| Olaparib (AZD2281) | Astra Zeneca | Phase 3 studies in adjuvant and advanced settings in germline BRCAm breast cancer |
| Veliparib (ABT-888) | Abbvie | Phase 3 study in neoadjuvant setting in combination with carboplatin and standard therapy in triple-negative breast cancer |
| Phase 2/3 studies in advanced setting as combination therapy in germline BRCAm breast cancer | ||
| Niraparib (formerly MK-4827) | Tesaro | Phase 3 study in advanced setting in germline BRCAm breast cancer |
| Talazoparib (BMN-673) | BioMarin Pharmaceuticals | Phase 3 study in advanced setting in germline BRCAm breast cancer |
| Phase 2 studies in advanced setting in BRCAm breast cancer | ||
| Phase 2 study in advanced setting in germline BRCA intact breast cancer | ||
| Phase 2 study in neoadjuvant setting in BRCAm breast cancer | ||
| Rucaparib (formerly AG-14699) | Clovis Oncology | Phase 2 study in advanced setting in patients with known germline BRCAm solid tumors |
| Phase 2 study in adjuvant setting in triple-negative breast cancer or germline BRCAm breast cancer | ||
| CEP-9722 | Teva Pharmaceutical Industries | Phase 2 study in advanced setting in solid tumors |